WuXi Biologics, a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Almirall, a skin-health focused global pharmaceutical company, have signed a collaboration agreement enabling Almirall to leverage the proprietary WuXiBody platform to develop bispecific antibodies for dermatological diseases.   Almirall gains access to WuXi Biologics’ proprietary antibody platforms including WuXiBody, a versatile bi...